The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teplizumab (Tzield) to delay the onset of Stage 3 type 1 diabetes (T1D) by an average of three years in adults and children ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results